A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807
This study is recruiting at 34 US sites in 18 states, according to its ClinicalTrials.gov record last updated .
Summary
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Neoplasms
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Southern Cancer Center (SCC) ( Site 8000) · Daphne, AL
Arizona · 1
- The University of Arizona Cancer Center - North Campus ( Site 0055) · Tucson, AZ
California · 2
- Los Angeles Hematology Oncology Medical Group ( Site 0026) · Los Angeles, CA
- Hoag Memorial Hospital Presbyterian ( Site 0025) · Newport Beach, CA
Colorado · 1
- St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021) · Grand Junction, CO
Delaware · 1
- Medical Oncology Hematology Consultants (MOHC) ( Site 8002) · Newark, DE
Florida · 2
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0024) · Altamonte Springs, FL
- Comprehensive Hematology Oncology ( Site 0060) · St. Petersburg, FL
Kentucky · 2
- Baptist Health Hamburg ( Site 0071) · Lexington, KY
- Baptist Health Lexington ( Site 0050) · Lexington, KY
New Jersey · 2
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) · Hackensack, NJ
- Rutgers Cancer Institute of New Jersey ( Site 0033) · New Brunswick, NJ
New Mexico · 3
- Presbyterian Kaseman Hospital ( Site 0072) · Albuquerque, NM
- University of New Mexico Comprehensive Cancer Center ( Site 0047) · Albuquerque, NM
- Presbyterian Rust Jorgensen Cancer ( Site 0073) · Rio Rancho, NM
New York · 2
- Queens Hospital Cancer Center ( Site 0011) · Jamaica, NY
- Optum Medical Care, PC ( Site 0009) · Westbury, NY
North Carolina · 2
- Novant Health Cancer Institute ( Site 0019) · Charlotte, NC
- Novant Health Oncology Specialists ( Site 0074) · Winston-Salem, NC
Ohio · 1
- TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0020) · Cincinnati, OH
Pennsylvania · 2
- University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058) · Pittsburgh, PA
- Cancer Care Associates Of York ( Site 0063) · York, PA
Tennessee · 2
- SCRI Oncology Partners ( Site 7000) · Nashville, TN
- Tennessee Oncology ( Site 0068) · Nashville, TN
Texas · 6
- Texas Oncology - DFW ( Site 8003) · Dallas, TX
- JPS Health Network ( Site 0067) · Fort Worth, TX
- Oncology Consultants P.A. ( Site 0061) · Houston, TX
- Texas Oncology - Gulf Coast ( Site 8006) · Houston, TX
- Texas Oncology - Central/South Texas ( Site 8005) · McAllen, TX
- Mays Cancer Center ( Site 0049) · San Antonio, TX
Virginia · 2
- Virginia Oncology Associates (VOA) ( Site 8001) · Norfolk, VA
- Shenandoah Oncology ( Site 8004) · Winchester, VA
Washington · 1
- Northwest Medical Specialties, PLLC ( Site 0062) · Tacoma, WA
Wisconsin · 1
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039) · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.